FDA’s SaMD/SiMD Guidance Could Mean Documentation Headaches For Some Software Makers, Attorney Says
Executive Summary
A long-awaited draft guidance from the US agency delineates which medical software devices will need additional documentation based on risk – but it could also mean more work for some manufacturers.
You may also be interested in...
Lifting The Hood On MDUFA V
The document includes promises from the US FDA related to review timelines, consensus standards, the Total Product Life Cycle pilot, and more.
Global Medtech Guidance Tracker: November 2021
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Forty-one documents have been posted on the tracker since its last update.
MDUFA IV Report: US FDA Needs To Publish Digital Health Guidance
Booz Allen Hamilton’s report found that for the most part the agency has fulfilled its user fee obligations – but one major shortcoming is an unpublished digital health guidance.